The global programmeddeath-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors market is
valued at an estimated $4,926.4 million in 2016, and it is expected to grow at
a CAGR of 23.4% during 2017 - 2025. The growth of the global market is largely
driven by the increased investment and funding, strong pipeline, and improved
safety and efficacy.
Some of the other
factors driving the growth of the global market include technological
advancements and innovations, and high prevalence of cancer. Less number of
competitors and expected launch of Phase III drug candidates will create ample
growth opportunities for the global market. However, high cost of research and
therapy, and stringent and time consuming regulatory process are the key
barriers for the growth of the global market.
PD-1 and PD-L1
inhibitors are highly growing immunotherapies that are being used in oncology
therapy area. The pipeline of PD-1 and PD-L1 inhibitors is enriched with 47
drugs and there are approximately 245 active clinical studies. There are many
drugs in early stage of pipeline; thus, making PD1
and PDL1 inhibitors market very lucrative.
Download Free Sample of This Research Report: https://www.psmarketresearch.com/market-analysis/pd1-and-pdl1-inhibitors-market/report-sample
